GSK "to pay $460 million" to settle bulk of US Avandia claims out of a total $2.4 billion Q2 legal bill
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has reportedly agreed to pay around $460 million to resolve around 10,000 Avandia (rosiglitazone) lawsuits (out of the roughly 11,000 suits outstanding) from US patients or family members alleging that use of the product led to injury, according to the Bloomberg news service, citing people familiar with the accords. The figure pales next to the $2.36 billion GSK said it expected to record in legal charges during the second quarter in a statement released today by the pharma giant.